Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Distribution, selling, general and administrative expenses

Restructuring and employee severance

Amortization and other acquisition-related costs

Impairments and (gain)/loss on disposal of assets, net

Litigation (recoveries)/charges, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cardinal Health

Cordis develops and manufactures medical devices for diagnostics and interventional procedures to treat patients suffering from coronary and peripheral vascular diseases.On October 4, 2015, Cardinal Health announced that it has completed the acquisition of Johnson & Johnson's Cordis business for $1.944 billion.

Cordis

Cardinal Health, Inc. is a healthcare services and products company, which engages in the provision of customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices. It also provides medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency. The firm operates through the Pharmaceutical and Medical segments. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products. The Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical, and laboratory products. The company was founded by Robert D. Walter in 1979 and is headquartered in Dublin, OH.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Cardinal Health reports strong Q3 results, focuses on Pharma growth

Cardinal Health's Q3 results demonstrated strong performance in the Pharma segment, while the Medical segment faced challenges. The company raised its guidance for the year and emphasized the importance of Red Oak Sourcing in maintaining market dynamics. Looking ahead, the company is focused on executing its medical improvement plan and maximizing shareholder value.

Cardinal Health reports stable Q2 growth, eyes Pharma segment

Cardinal Health's Q2 2023 performance showcased stability and growth in the Pharma segment, with a return to profitability in the Medical segment.
The company's strategic focus on executing key priorities and driving shareholder value creation is evident in its financial results.
Challenges such as international freight costs and supply chain headwinds are being addressed, while opportunities in COVID therapies, pricing strategy, and growth investments are being pursued.
Overall, Cardinal Health's revised outlook and strong performance in key segments position it for continued growth and financial success.

Cardinal Health reports robust Q3 earnings, eyes biosimilars for growth

Cardinal Health delivered strong financial performance in Q3 2023, driven by robust growth in the Pharma segment.
While facing challenges in the Medical segment, the company remains focused on mitigating inflation and maximizing shareholder value.
With a positive outlook on future growth opportunities, Cardinal Health aims to address cost pressures and drive profitability.

Cardinal Health achieves record results, raises guidance for fiscal '24

Cardinal Health's strong performance in Q4 and fiscal year 2023, coupled with strategic initiatives and guidance raise, position the company for continued growth and success.
Challenges such as inflation mitigation and cost pressures are being addressed, while opportunities in organic growth and strategic investments pave the way for future profitability.
The company's focus on advancing Pharma, executing the Medical Improvement Plan, and maximizing shareholder value creation underscores its commitment to sustained growth and value creation.

Cardinal Health reports strong Q1 earnings, raises guidance for FY24

Cardinal Health's Q1 2024 earnings call showcased robust performance, with profit growth in both Pharma and Medical segments. The company raised EPS guidance, demonstrated strong cash flow generation, and emphasized customer service and shareholder value creation. Challenges include managing margins, nonoperating items, and commodity price impacts, while opportunities lie in healthcare sector growth, innovation, and market dynamics.

Cardinal Health reports robust Q2 earnings, raises EPS guidance

Cardinal Health's Q2 performance reflects strong revenue growth, improved cash flow, and raised EPS guidance, supported by strategic acquisitions and growth initiatives.
While facing challenges from nonrecurring adjustments and SG&A growth, the company remains focused on core businesses and driving future growth opportunities.
With a positive outlook on market-driven growth, cost management, and strategic priorities, Cardinal Health aims to sustain its momentum and deliver value to shareholders.

Cardinal Health reports robust Q3 earnings, eyes growth opportunities ahead

Cardinal Health's Q3 performance reflects strong financial results and strategic progress across key segments, with raised guidance for fiscal '24 and '25.
The company faces challenges such as managing customer transitions and inflationary impacts but is well-positioned to capitalize on growth opportunities.
By focusing on cost optimization, strategic partnerships, and customer-centric solutions, Cardinal Health aims to drive sustained growth and profitability.
Investments in technology, brand growth, and operational efficiency underscore Cardinal Health's commitment to delivering value to shareholders and customers.

Cardinal Health excels in fiscal '24, raises guidance for '25

Cardinal Health's strong performance in fiscal year '24, highlighted by record financial results and strategic progress, positions the company for continued success.
Despite challenges such as market dynamics and customer transitions, the company's raised guidance for fiscal year '25 underscores confidence in future growth.
By capitalizing on strengths like revenue growth in key segments and making strategic investments, Cardinal Health is poised to navigate challenges and seize opportunities for sustained growth.

Cardinal Health reports strong Q1 performance and raises fiscal guidance

Cardinal Health's Q1 performance showed strength in Pharma and Specialty Solutions despite revenue decrease.
Challenges in GMPD segment and nuclear supply disruptions are being addressed for minimal impact.
Opportunities lie in continued cost reductions, growth normalization, and operational improvements.
Overall, Cardinal Health is well-positioned to navigate challenges and capitalize on growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DUBLIN, Ohio, Aug. 11, 2021 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that it has extended its agreements with CVS Health to distribute pharmaceuticals to retail pharmacies and distribution centers through June 30, 2027. "We value our long-standing partnership with CVS Health, and we are honored to continue our important work together to bring our best-in-class abilities together for their customers," stated Mike Kaufmann, CEO of Cardinal Health.

Cardinal Health Extends Pharmaceutical Distribution Agreements with CVS Health

DUBLIN, Ohio, Aug. 10, 2021 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today announced its efforts to commercialize and broaden access to over-the-counter rapid COVID-19 tests through partnerships with Abbott and Quidel Corporation ("Quidel"). Cardinal Health will leverage its expansive distribution network to support broad access to Quidel's QuickVue® At-Home OTC COVID-19 Test and Abbott's BinaxNOW™ COVID-19 Antigen Self-Test, which allow consumers to easily perform tests for the virus without a prescription.

Cardinal Health partners with Abbott and Quidel to offer rapid OTC COVID-19 tests

Bank of Nova Scotia

Clorox

Corteva Inc

Norfolk Southern

Oracle

T. Rowe Price Group

In July, we (my wife and I) received a total of $1,147.79 of dividend income. Despite the pandemic from COVID-19, dividend income continues to grow, due primarily to additional investment and reinvestment.

Dividend Income Summary: Lanny's July 2021 Summary

American Express

Colgate-Palmolive

FireEye

Lowe's

Livent Corp

Although the economy appears to be booming, skeptical investors may want to consider these recession-resistant stocks to buy. The post 7 Recession-Resistant Stocks To Buy if You're Feeling Nervous appeared first on InvestorPlace.

7 Recession-Resistant Stocks To Buy if You're Feeling Nervous

Cardinal Health (NYSE: CAH) reported fourth-quarter adjusted earnings today that were only two-thirds of what The Street expected. The Company posted an adjusted EPS of $0.77, behind analysts' estimate of $1.20.

Cardinal Health Stock Loses 14% As Q4 Earnings Disappoint; Expects COVID-19 Tailwinds To Impact FY22

Shares of Cardinal Health Inc. tumbled 13.7% toward a nine-month low in afternoon trading Thursday, after the distributor of drugs and laboratory products reported a big fiscal fourth-quarter earnings miss, and provided a downbeat outlook, as results were hurt by a $197 million COVID-related inventory reserve, related to personal protective equipment. The stock, which paced the S&P 500's decliners, was also on track to suffer the biggest one-day selloff since May 2018.

Cardinal Health stock tumbles to pace S&P 500 losers, after big Q4 profit miss and downbeat outlook

Investors are reading a lot (perhaps too much) into an accounting decision made in the early days of the COVID-19 pandemic.

Why Cardinal Health Is Down Nearly 13% Today

Cardinal Health, Inc. (CAH) CEO Mike Kaufmann on Q4 2021 Results - Earnings Call Transcript

Although Cardinal Health (CAH) witnessed margin contraction in its fiscal fourth-quarter results, rise in revenues in both its segments is encouraging.

Cardinal Health (CAH) Q4 Earnings Lag, Revenues Top Estimates

DUBLIN, Ohio, Aug. 5, 2021 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported that fourth-quarter fiscal 2021 revenue increased 16% to $42.6 billion. This increase includes the favorable prior year comparison from reduced pharmaceutical demand related to COVID-19.

Cardinal Health reports fourth quarter and full year results for fiscal year 2021

DUBLIN, Ohio, Aug. 2, 2021 /PRNewswire/ -- Cardinal Health (NYSE: CAH) and Hellman & Friedman (H&F) announced today the completion of the previously announced sale of Cardinal Health's Cordis business to H&F. The sale price of approximately $1 billion includes the buyer's assumption of certain liabilities and the seller's retention of certain working capital accounts.

Cardinal Health completes sale of Cordis business to Hellman & Friedman

AppFolio

Citrix Systems

Ionis Pharma

PG&E

Perrigo

Splunk

In a churning market like this, you want to steer clear of stocks that are floundering. Here are sevens stocks to avoid today.

7 F-Rated Stocks to Avoid for the Rest of 2021

Becton, Dickinson and Co.

Medtronic

You can combine high-quality companies with mega-trends that are favorable for long-term growth with these dividend healthcare stocks. The post 3 Healthcare Stocks for Dividend Growth appeared first on InvestorPlace.

3 Healthcare Stocks for Dividend Growth

Amgen

McKesson

Newell Brands

Starbucks

These companies could borrow money at lower rates and use the proceeds to buy back stock—making their shares more attractive to investors.

5 Stocks to Play Low Interest Rates—While They Last

AmerisourceBergen

Johnson & Johnson

Attorney generals of several states reach settlement deal with J&J (JNJ) and three drug distributors - MCK, CAH and ABC - related to thousands of opioid abuse litigations. Non-participating states may join the deal soon.

US States Get $26B Settlement Deal in Opioid Abuse Litigation

States unveiled a historic $26 billion settlement with drug companies to resolve thousands of opioid-crisis lawsuits, paving the way for communities across the country to secure a jolt of funding to address an epidemic in painkiller addiction that hasn't abated.

The Wall Street Journal: States announce $26 billion settlement to resolve opioid lawsuits

CONSHOHOCKEN, Pa. & DUBLIN, Ohio & IRVING, Texas--(BUSINESS WIRE)--AmerisourceBergen (NYSE: ABC), Cardinal Health (NYSE: CAH) and McKesson (NYSE: MCK) announced today that they have negotiated a comprehensive proposed settlement agreement which, if all conditions are satisfied, would result in the settlement of a substantial majority of opioid lawsuits filed by state and local governmental entities. While the companies strongly dispute the allegations made in these lawsuits, they believe the pr

Distributors Announce Proposed Opioid Settlement Agreement

The three largest U.S. drug distributors agreed mid-trial to pay up to $1.18 billion to settle claims by New York state and two of its biggest counties over their role in the nationwide opioid epidemic, the state's attorney general said on Tuesday. McKesson, Cardinal Health and AmerisourceBergen settled as state attorneys general prepare to announce.

Drug distributors agree to settle New York opioid claims for up to $1.18B

NEW YORK, July 20 (Reuters) - The three largest U.S. drug distributors agreed mid-trial to pay up to $1.18 billion to settle claims by New York state and two of its biggest counties over their role in the nationwide opioid epidemic, the state's attorney general said on Tuesday.

Drug distributors settle New York opioid claims for up to $1.18 bln

McKesson Corporation (NYSE: MCK), Cardinal Health Inc (NYSE: CAH), and AmerisourceBergen Corp (NYSE: ABC) have agreed to pay up to $1.179 billion to settle claims by New York state and two of its biggest counties over their role in the U.S. opioid epidemic. The drug distributors settled as state attorneys general prepare to announce a $26 billion deal with the distributors and drugmaker Johnson & Johnson (NYSE: JNJ), resolving cases as soon as this week.

Drug Distributors To Pay Up To $1.1B To Settle New York Opioid Claims

Shares of McKesson Corp. , Cardinal Health Inc. and AmerisourceBergen Corp. all surged more than 4% in morning trading Tuesday, after the New York Attorney General Letitia James announced a $1.1 billion settlement agreement with the drug distributors to combat the opioid epidemic. James said the agreement resolves claims for the companies' role in helping fuel the epidemic, and will remove the companies from the ongoing opioid trial.

McKesson, Cardinal Health, AmerisourceBergen stocks surge after $1.1 billion opioid settlement with NY AG

CENTRAL ISLIP, N.Y.--(BUSINESS WIRE)--AmerisourceBergen (NYSE: ABC), Cardinal Health (NYSE: CAH) and McKesson (NYSE: MCK) announced today that they have agreed to pay up to $1.179 billion in a settlement with the State of New York and its participating subdivisions, including Nassau and Suffolk Counties, to resolve opioid-related claims. This settlement was negotiated in connection with the ongoing negotiations toward a broad resolution under the previously disclosed settlement framework intend

Distributors Reach Opioid Settlement Agreement With New York State

Cardinal Health (CAH) launches NavixRx Compliance Packaging and E-Commerce Storefront to allow independent pharmacists to expand services and support medication adherence.

Cardinal Health (CAH) Introduces 2 New Digital Solutions

DUBLIN, Ohio, July 15, 2021 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today launched two new innovative solutions – Cardinal HealthTM NavixRxTM Compliance Packaging and E-Commerce Storefront – to help independent pharmacies meet changing consumer expectations and offer personalized and convenient on-demand services. NavixRxTM Compliance Packaging NavixRxTM Compliance Packaging provides independent pharmacies a solution to outsource compliance packaging for patients taking two or more prescriptions daily.

Cardinal Health launches NavixRx™ Compliance Packaging and E-Commerce Storefront

West Pharmaceutical Services

Despite the COVID-19 pandemic induced challenges, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical-Dental Supplies industry. MCK, WST and CAH are well-poised to gain from the prospects.

News for Cardinal Health Stock (CAH)